2 Additionally, among those with EGFR- mutant disease, the confirmed ORR was 43.6%, with a disease control rate (DCR) of 82.1% and a median DOR of 7.0 months
This approach reduced the level of paralysis and preserved myelin integrity, demonstrating a single-dose route to reset immune tolerance
Quicksilver Scientific A practitioner's approval is required to purchase Quicksilver Scientific
Not all individuals will qualify for medication-based treatment
This may be due to two important limitations of the TfR as target: off-target effects in TfR-rich peripheral tissues, including liver, spleen and lungs, and receptor saturation
This is uncommon but might contribute to symptoms in some patients, particularly those taking certain medications like diuretics